The chief oncologist of the Ministry of Health, General Director of the National Medical Research Center for Radiology, Andrey Kaprin, announced the temporary suspension of the recruitment of candidates to participate in the first phase of a clinical trial of an oncolytic cancer vaccine.
The domestic development "EnteroMix" showed high efficiency during preclinical studies, and the Ministry of Health and Roszdravnadzor allowed it to proceed to the next stage of study. Studies at the National Medical Research Center for Radiology of the Ministry of Health of Russia will focus on studying the safety, tolerability, and pharmacokinetics of the drug, created on the basis of enteroviruses. And in just a few days since its announcement on December 17, doctors received "a record number of applications" from Russians to participate in them.
Due to the huge number of requests, we have decided to prematurely suspend the recruitment of candidates at this stage. This is necessary so that our specialists have time to carefully study each application and select those who meet the participation criteria. However, this is not the end. For all those who did not have time to apply, we inform you: there are two more recruitment waves ahead! We will continue to expand opportunities for participation in research, and we will definitely announce new stages as soon as their start is ready.
Kaprin did not name the exact number of people wishing to help Russian medicine. But, as the press service of the National Medical Research Center for Radiology of the Ministry of Health of Russia told RIA "European-Asian News", more than a thousand applications were submitted on the first day alone.
"EnteroMix" was developed at the National Medical Research Center for Radiology of the Ministry of Health of Russia in collaboration with the Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences. This vaccine is an important step in creating innovative methods for combating solid tumors. These include tumors of the head and neck, lung cancer, mediastinal tumors, breast cancer, tumors of the gastrointestinal tract, liver, biliary tract, pancreas, genitourinary system, primary tumors of the central nervous system, soft tissue and bone sarcomas, melanoma of the skin and mucous membranes.
Read materials on the topic:
Russia will provide itself with 90% of its own medical products by 2030 — VVP
